Cologne, Germany, July 25, 2011 / B3C newswire / - CEVEC Pharmaceuticals, licensing its human CAP® Technology based expression system for proteins and vaccines, today announced the closing of a €6M ...
- CEVEC adds laminins as CAP(R)Go application in the field of ex vivo cell culture products for cell therapies - CEVEC's CAP(R)Go to displace HEK293 and CHO cell lines in GMP manufacturing COLOGNE, ...
CAP-T system will be used to manufacture protein antigen being evaluated in preclinical studies. Swiss vaccines company Pevion Biotech negotiated an exclusive license option agreement with Cevec ...
Utilizing CAP-Go Cells for Optimizing Serum Half-Life and Glycosylation Profile Therapeutic proteins are of such clinical importance that they are undergoing accelerating development. Despite advances ...
Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies 46 scientific experts based in Cologne, Germany, join the Cytiva team in the genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results